Carlos Martin Esquivel1,2, Manuel Garcia3, Lucas Armando4,3, Guillermo Ortiz4,3, Fernando Martínez Lascano4,3,5, José María Foscarini4,5. 1. Sanatorio Allende, 384 Hipólito Yrigoyen Ave, 5000, Córdoba, Córdoba, Argentina. dresquivelcarlos@gmail.com. 2. Catholic University of Córdoba, 3555 Armada Argentina Avenue, 5000, Córdoba, Córdoba, Argentina. dresquivelcarlos@gmail.com. 3. Catholic University of Córdoba, 3555 Armada Argentina Avenue, 5000, Córdoba, Córdoba, Argentina. 4. Sanatorio Allende, 384 Hipólito Yrigoyen Ave, 5000, Córdoba, Córdoba, Argentina. 5. University of Villa María, 1555 Arturo Jauretche Avenue, 5900, Villa María, Córdoba, Argentina.
Abstract
INTRODUCTION: Obesity is strongly associated with non-alcoholic fatty liver disease (NAFLD); 66-99% of the obese population could suffer some grade of NAFLD. It can progress into cirrhosis, which is associated to hepatocellular carcinoma, and a liver transplant could be indicated. NAFLD represents the third cause of liver transplant, and it is expected to be the first by 2025. Sleeve gastrectomy (SG) is the most common bariatric procedure over the world. There is scant literature regarding NAFLD after SG, and there are no prospective studies published up to date. OBJECTIVE: To evaluate the evolution of NAFLD in patients with obesity after 1 year of SG. METHODS: From January 2009 to December 2013, intraoperative liver biopsy was performed in 63 obese patients who underwent SG. Forty-three patients were again biopsied 1 year after surgery. Demographics, body mass index, percentage of excess weight loss, liver function test, lipid panel, glucose panel, and histological changes were prospectively analyzed. RESULTS: One hundred percent of the patients reversed or reduced the stage of steatosis or steatohepatitis 12 months after surgery, obtaining a statistically significant difference for both steatosis and steatohepatitis. One patient presented complete cirrhosis regression in the pathology. Neither of the patients had worsened liver histology. CONCLUSIONS: NAFLD could be dealt with laparoscopic sleeve gastrectomy, preventing its progression into cirrhosis. SG can be performed in patients with obesity and metabolic syndrome, with NAFLD showing satisfactory results 12 months after surgery. NAFLD should be a formal indication for bariatric surgery.
INTRODUCTION: Obesity is strongly associated with non-alcoholic fatty liver disease (NAFLD); 66-99% of the obese population could suffer some grade of NAFLD. It can progress into cirrhosis, which is associated to hepatocellular carcinoma, and a liver transplant could be indicated. NAFLD represents the third cause of liver transplant, and it is expected to be the first by 2025. Sleeve gastrectomy (SG) is the most common bariatric procedure over the world. There is scant literature regarding NAFLD after SG, and there are no prospective studies published up to date. OBJECTIVE: To evaluate the evolution of NAFLD in patients with obesity after 1 year of SG. METHODS: From January 2009 to December 2013, intraoperative liver biopsy was performed in 63 obese patients who underwent SG. Forty-three patients were again biopsied 1 year after surgery. Demographics, body mass index, percentage of excess weight loss, liver function test, lipid panel, glucose panel, and histological changes were prospectively analyzed. RESULTS: One hundred percent of the patients reversed or reduced the stage of steatosis or steatohepatitis 12 months after surgery, obtaining a statistically significant difference for both steatosis and steatohepatitis. One patient presented complete cirrhosis regression in the pathology. Neither of the patients had worsened liver histology. CONCLUSIONS: NAFLD could be dealt with laparoscopic sleeve gastrectomy, preventing its progression into cirrhosis. SG can be performed in patients with obesity and metabolic syndrome, with NAFLD showing satisfactory results 12 months after surgery. NAFLD should be a formal indication for bariatric surgery.
Authors: Deepa V Cherla; Noe A Rodriguez; Roman Vangoitsenhoven; Tavankit Singh; Neal Mehta; Arthur J McCullough; Stacy A Brethauer; Philip R Schauer; Ali Aminian Journal: Surg Endosc Date: 2019-07-29 Impact factor: 4.584
Authors: Miller Barreto de Brito E Silva; Francisco Tustumi; Antonio Afonso de Miranda Neto; Anna Carolina Batista Dantas; Marco Aurélio Santo; Ivan Cecconello Journal: Obes Surg Date: 2021-04-13 Impact factor: 4.129
Authors: Matthew Barron; Hailey Hayes; Deemantha G Fernando; Aron M Geurts; Tammy L Kindel Journal: J Gastrointest Surg Date: 2022-05-26 Impact factor: 3.267